Clinical Trial Results: Mircera [methoxy polyethylene glycol-epoetin beta]

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Mircera in Patients With Non-Hodgkin’s Lymphoma and Anemia

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: II
A Study of Mircera in Anemic Patients With Multiple Myeloma.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study Comparing Mircera and Epeotin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients WIth Chronic Kidney Disease.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Maintenance Treatment of Pre-Dialysis Patients With Chronic Renal Anemia.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Correction of Anemia in Dialysis Patients.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease Not Treated With ESA or on Dialysis.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera in Dialysis Patients With Chronic Renal Disease and Anemia.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcuteneous Mircera for the Treatment of Anemia in Pre-Dialysis Patients.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Maintenance Treatment of Hemodialysis Patients With Chronic Renal Anemia.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study Comparing Subcutaneous Mircera and Darbepoetin Alfa for the Maintenance Treatment of Anemia in Kidney Transplant Patients.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not on Dialysis.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: IV
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Subcutaneous Mircera For The Maintenance Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Intravenous Mircera in Patients With Chronic Renal Anemia Who Are on Dialysis.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Predialysis Patients Not Treated With ESA.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
A Study of Once-Monthly Subcutaneous Mircera for the Treatment of Chronic Renal Anemia in Pre-Dialysis Patients Not Currently Treated With ESA.

Product Name: Mircera [methoxy polyethylene glycol-epoetin beta]
Date of Report: To be Published
Phase: III
CARISMA Study: A Study of Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.